Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
| Autor: | Goffin, J.R., Straume, O., Chappuis, P.O., Brunet, J.-S., Bégin, L.R., Hamel, N., Wong, N., Akslen, L.A., Foulkes, W.D., Bégin, L R |
|---|---|
| Předmět: |
BREAST cancer
NEOVASCULARIZATION SURVIVAL analysis (Biometry) CANCER in women PROTEIN metabolism SURVIVAL RESEARCH GENETIC mutation ENDOTHELIUM BRCA genes RESEARCH methodology PROGNOSIS METASTASIS EVALUATION research CELL division TUMOR classification COMPARATIVE studies PATHOLOGIC neovascularization IMMUNOENZYME technique BREAST tumors |
| Zdroj: | British Journal of Cancer; 9/15/2003, Vol. 89 Issue 6, p1031-1034, 4p |
| Abstrakt: | Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival (relative risk 1.9, 95% CI: 1.2-3.0), particularly among women who received adjuvant chemotherapy (10-year survival 27 vs 69%, P=0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|